Ph.D., Robert and Dorothy Markin Professor and Chair, Department of Biomedical Genetics, Director of Research & Co-Director, Wilmot Cancer Institute, University of Rochester Medical Center, NY
Dr. Land has contributed pioneering work on the role of oncogenes and their cooperative nature in cancer during the last three decades. In 2015 he received the “Outstanding Investigator Award” from NCI that provides long-term research support. Currently his research focuses on non-mutated genes downstream of oncogenic mutations that are critical to many types of cancer cells. The goal of his research is to find novel paths to targeted and personalized cancer therapies that are independent of the tumors’ mutational status and thus could be applied to many patients. He is the Robert & Dorothy Markin Professor and inaugural Chair of the Department of Biomedical Genetics at the University of Rochester Medical Center in Rochester, New York, where he works since 1999. Dr. Land also currently serves as the Director of Research and Co-Director of the James P. Wilmot Cancer Center at URMC.
Session Abstract – PMWC 2019 Silicon Valley
Session Synopsis: Genetic data have a limited impact in personalized cancer medicine without cell biological phenotype data. However, reproducible multiomics databases are not existing, yet. The session will address the major challenge, i.e. routine collection of tissue in multi-center studies of global scale that fulfill the preanalytical requirement for multiomic databases.